Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.

Item

http://www.wikidata.org/entity/Q31149381

Q31149381

about

Defining the blanks--pharmacochaperoning of SLC6 transporters and ABC transporters Genetics of Common Antipsychotic-Induced Adverse Effects Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations.mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism A network-based approach to prioritize results from genome-wide association studies.An integrative method for scoring candidate genes from association studies: application to warfarin dosing.Genome-wide association studies in pharmacogenomics: successes and lessons.Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia.HGPGD: the human gene population genetic difference database.Identification of 4-Trimethylaminobutyraldehyde Dehydrogenase (TMABA-DH) as a Candidate Serum Autoantibody Target for Kawasaki Disease.Pharmacogenetics in psychiatry: are we ready for widespread clinical use?GABA(A) receptor downregulation in brains of subjects with autism.Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.Individualizing clozapine and risperidone treatment for schizophrenia patients.From Prader-Willi syndrome to psychosis: translating parent-of-origin effects into schizophrenia research.Clinical association between pharmacogenomics and adverse drug reactions.Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries.Pharmacogenomic genome-wide association studies: lessons learned thus far.A dimension reduction approach for modeling multi-locus interaction in case-control studies.Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia.DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia.A Review of Pathway-Based Analysis Tools That Visualize Genetic Variants.Association study between the neurexin-1 gene and tardive dyskinesia.A functional SNP catalog of overlapping miRNA-binding sites in genes implicated in prion disease and other neurodegenerative disorders.Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.Management of common adverse effects of antipsychotic medications

P2860

Q26825537-34643B66-6A36-4843-BB79-0C88A29899C0 Q28072893-2988F6B0-07D6-413C-B851-6D6C576692C0 Q28729947-B7ACBCDF-5075-44E3-ADF8-7441401503AE Q33707734-BE0618C2-BC01-44E4-B699-77A9899ECCD8 Q33833647-92D909F4-3FAA-46BA-87FC-E0691AA4FAE9 Q34018953-0E95F064-7DD3-4F7B-B948-6AE7546430AE Q34147587-32F5683A-F1CB-43A2-BD6F-B81591BEDED5 Q34415006-24249A89-E702-4DFB-B940-C0CFF5B0AD41 Q34506671-55BA430D-7B25-4E57-8BF1-AAD890CB980D Q34660856-61218A82-C8C8-4503-90A3-C759A833D540 Q34745339-53AA6F04-E88C-4E70-BA69-42051E59AF31 Q35641080-7E8B18BF-B692-46EF-AEE2-207E2990D39B Q37076472-2EBE932D-8992-42A2-B8F1-6B73FB2C5699 Q37229115-4B2E585E-2CA7-4F82-9550-A27D8E28FED7 Q37264543-D9E42C54-4BE2-4982-B013-F6899BCB9B28 Q37678047-E2BB8946-3AA9-4784-8FEB-0EFD1853D3F1 Q37952823-F676D97B-E8B4-4DED-8AD1-101CF87AF656 Q37960512-CFF8EA89-4468-4910-A33C-3764472B3E00 Q38032249-45E430C5-3F3D-4FD9-A4C2-5F261083A126 Q38061501-3711B604-E3A3-4084-AE7F-9BE1CA93AF0A Q38170458-DC4534B7-AB3A-4C87-A006-B9701048D625 Q38296769-CB96C727-9304-4ECB-8A6B-D8B440CB9CF6 Q38431150-6AF539D6-6984-4838-AF34-3F82A482FDA6 Q38911685-DCD568DB-6E80-4C34-8C32-63965AE16746 Q39359391-3E89D324-552E-4F05-A895-7CC1B88E9129 Q41874051-0E497C62-67CB-4F61-86F8-870139DEFBB1 Q42808018-62145BF0-F29B-4E66-8C62-86011336B500 Q44208517-E182A394-380E-4530-A4F5-766FE34D0C44 Q44284561-5AE59A7F-4C48-4E1E-AE44-1B92DF5F1791 Q44582314-4EF18AF5-3D86-46C3-9DAE-6928B2127057 Q47159542-74965307-7176-4F35-8433-8B7E6A704988 Q47818805-149177E9-CB70-4C3F-A759-C89C0C604525 Q47990584-9BDF4890-3AAB-4F2F-BA41-0AAB4CBE80EF Q50794479-374142F2-EB3D-4B34-800E-E39EEA823CD2 Q58760350-DB6A2EB2-B023-4295-A7EF-5D9946D6556A

P2860

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.

Item

http://www.wikidata.org/entity/Q31149381

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu